Document:

<PAGE>   1
                                                                    Exhibit 10.9

CS93-27

                 SPONSORED RESEARCH AGREEMENT FOR CLINICAL STUDY

         Agreement, made this 11th day of February, 1993, by and between THE
UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (hereinafter referred to as
"CANCER CENTER"), a component institution of The University of Texas System
(hereinafter referred to as "SYSTEM"), located in Houston, Texas, and Texas
Biomedical Development Partners (hereinafter referred to as "SPONSOR"), located
in Austin, Texas.

                                   WITNESSETH:

         WHEREAS, CANCER CENTER has research facilities and situations which
would allow clinical investigation and study of the "Clinical Protocol for
Modification of Oncogene and tumor Suppressor Gene Expression in Non-Small Cell
Lung Cancer (NSCLC)" as described in Exhibit I hereinafter referred to as
("Research"), a copy of which is attached hereto and incorporated herein by
reference; and

         WHEREAS, both SPONSOR and CANCER CENTER consider it necessary and
desirable and desirable to perform the Research;

         NOW, THEREFORE, the parties agree as follows:

1. Evaluation. SPONSOR agrees to engage the services of CANCER CENTER as an
independent contractor to perform the Research. The Research will be under the
supervision of Jack A. Roth, M.D. (Principal Investigator) at CANCER CENTER,
with the assistance of appropriate associates and colleagues at CANCER CENTER as
may be required.

2. Research. CANCER CENTER agrees as an independent contractor to conduct the
Research. Such Research was originally approved by CANCER CENTER in accordance
with CANCER CENTER policy and may be subsequently amended only in accordance
with CANCER CENTER policy and the written agreement of CANCER CENTER and SPONSOR
as provided for in Article 15 herein below.

3. Invention and Patents.

         a. For all purposes herein, "Invention" shall mean any discovery,
concept or idea whether or not patentable or copyrightable, which (i) arises out
of work performed pursuant to the obligations of this Agreement; (ii) is
conceived and reduced to practice during the term of the Agreement as defined in
Article 13 hereinbelow; and (iii) includes but is not limited to processes,
methods, software, formulae, techniques, compositions of matter, devices, and
improvements thereof and know-how relating thereto. Inventions made solely by
the Principal Investigator and/or other CANCER CENTER personnel as identified in
Article 1 hereinabove or agents of CANCER CENTER shall be the sole property of
CANCER CENTER.

         b. In the event that an Invention is made, CANCER CENTER agrees to
include such Invention in the Option Agreement of December 17, 1992 (attached
hereto as Exhibit III) previously
<PAGE>   2
entered in to by CANCER CENTER and SPONSOR and give notice of such Invention to
SPONSOR within thirty (30) days of the identification of such Invention.

4. Confidentiality. In the course of work performed pursuant to the Research
under this Agreement, should either party provide confidential information to
the other party, the recipient party shall, until three (3) years after the
termination of this Agreement, maintain the confidentiality of that information
as it maintains the confidentiality of its own confidential information, and
shall not disclose such confidential information to any other party, nor shall
the recipient party disclose the disclosing party's confidential information to
the recipient's employees other than those employees having a "need-to-know."
Confidential information shall be clearly marked as such. If disclosed orally,
the party making the disclosure shall be responsible for clearly informing the
recipient party of the confidentiality of the information disclosed.
Notwithstanding the other provisions of this paragraph, nothing disclosed
hereunder shall be construed as confidential information which:

         a. is or becomes available to the public (except by a breach of this
Agreement by a party hereto);

         b. is rightfully received from another party not under obligation of
confidentiality to the disclosing party;

         c. is not known by the recipient party, or is independently developed
by the recipient party by persons without access to the confidential
information;

         d. is approved for release by the party designating the information as
confidential;

         e. is not identified as confidential at the time of disclosure;

         f. is not in writing or physical form at time of disclosure or reduced
to a written or physical form and identified as confidential within thirty (30)
days of disclosure; or

         g. is required to be disclosed under the laws of the United States of
America or the State of Texas or other governmental bodies, provided that the
parties shall first exhaust all reasonable measures available to protect the
confidentiality of such information upon disclosure.

5. Publication Rights. Notwithstanding the provisions of Article 4 of this
Agreement, CANCER CENTER may publish scientific papers relating to the
collaborative research performed under this Agreement. In the event that CANCER
CENTER wishes to publish, CANCER CENTER shall notify SPONSOR of its desire to
publish [ * ] in advance of publication and shall furnish to SPONSOR a written
description of the subject matter of the publication in order to permit SPONSOR
to review and comment thereon.

6. Publicity. CANCER CENTER acknowledges SPONSOR'S intention to distribute
periodically information releases and announcements to the news media regarding
the progress of research hereunder. SPONSOR shall not release such materials
containing the name of CANCER CENTER or any of its employees without prior
written approval by an authorized representative of CANCER CENTER, and

      [*] Certain information on this page has been omitted and filed
          separately with the Commission. Confidential treatment has been
          requested with respect to the omitted portions.

                                      -2-
<PAGE>   3
said approval shall not be unreasonably withheld. Should CANCER CENTER reject
the news release, CANCER CENTER and SPONSOR agree to discuss the reasons for
CANCER CENTER's rejection, and every effort shall be made to develop an
appropriate informational news release within the bounds of accepted academic
practices. SPONSOR reserves the same right in the event that CANCER CENTER
desires to distribute a news release concerning the research program. Nothing
herein shall be construed as prohibiting CANCER CENTER or SPONSOR from reporting
on this study to a governmental agency.

7. Responsibility. The parties each agree to assume individual responsibility
for the actions and omissions of their respective employee, agents and assigns
in conjunction with this evaluation.

8. Independent Contractor. SPONSOR will not have the right to direct or control
the activities of CANCER CENTER in performing the services provided herein, and
CANCER CENTER shall perform services hereunder only as an independent
contractor, and nothing herein contained shall be construed to be inconsistent
with this relationship or status. Under no circumstances shall CANCER CENTER be
considered to be an employee or agent of SPONSOR. This Agreement shall not
constitute, create or in any way be interpreted as a joint venture, partnership
or formal business organization of any kind.

9. Title to Equipment. CANCER CENTER shall retain title to all equipment
purchased and/or fabricated by it with funds provided by SPONSOR under this
Agreement.

10. Survivorship. The provisions of Articles 3, 4, 5, 6, and 12 shall survive
any expiration or termination of this Agreement.

11. Assignment. This Agreement may not be assigned by either party without the
prior written consent of the other party; provided, however, that SPONSOR may
assign this Agreement to any purchaser or transferee of all or substantially all
of SPONSOR's business upon prior written notice to CANCER CENTER.

12. Indemnification. CANCER CENTER shall, to the extent authorized under the
Constitution and the laws of the State of Texas, hold SPONSOR harmless from
liability resulting from the negligent acts or omissions of CANCER CENTER, its
agents or employees pertaining to the activities to be carried out pursuant to
the obligations of this Agreement; provided, however, that CANCER CENTER shall
not hold SPONSOR harmless from claims arising out of the negligence of SPONSOR,
its officers, agents or any person or entity not subject to CANCER CENTER's
supervision or control.

SPONSOR shall indemnify and hold harmless SYSTEM, CANCER CENTER, their regents,
officers, agents and employees from any liability or loss resulting from
judgments or claims against them arising out of the activities to be carried out
pursuant to the obligations of this Agreement or the use by SPONSOR of the
results of the Research, provided, however, that the following is excluded from
SPONSOR's obligation to indemnify and hold harmless:

         a. the negligent failure of CANCER CENTER to comply with any applicable
governmental requirements; or

                                       -3-
<PAGE>   4
         b. the negligence or willful malfeasance by a regent, officer, agent or
employee of CANCER CENTER or SYSTEM.

13. Award. SPONSOR agrees to pay CANCER CENTER a fee of Five Hundred Fifteen
Thousand and No/100 Dollars ($515,000.00) for expenses and other related costs
incurred in conjunction with the Research. This fee, as shown by approximate
category of expense in Exhibit II, which is attached hereto and is incorporated
herein by reference, for information only, shall be payable in Four (4) equal
installments of One Hundred Twenty-Eight Thousand Seven Hundred Fifty and No/100
Dollars ($128,750.00) each by SPONSOR to CANCER CENTER. The first such
installment shall be due within thirty (30) days of the date of execution of
this Agreement. The subsequent installments shall be due and payable as follows:
(a) three (3) months after execution, (b) six (6) months after execution and (c)
nine (9) months after execution.

14. Basic Term. This Agreement shall become effective as of the date first
hereinabove written and unless earlier terminated as hereinafter provided, shall
continue in force for a period of Eighteen (18) months after the same.

15. Default and Termination. In the event that either party to this Agreement
shall be in default of any of its material obligations hereunder and shall fail
to remedy such default within [*] after receipt of written notice thereof, the
party not in default shall have the option of terminating this Agreement by
giving written notice thereof, notwithstanding anything to the contrary
contained in this Agreement. Termination of this Agreement shall not affect the
rights and obligations of the parties which accrued prior to the effective date
of termination. SPONSOR shall pay CANCER CENTER for all reasonable expenses
incurred or committed to be expended as of the effective termination date,
subject to the maximum amount as specified in Article 13.

16. Entire Agreement. The parties acknowledge that this Agreement and the
attached Exhibits hereto represent the sole and entire Agreement between the
parties hereto pertaining to the Research and that such supersedes all prior
Agreements, understandings, negotiations and discussions between the parties
regarding same, whether oral or written. There are no warranties,
representations or other Agreements between the parties in connection with the
subject matter hereof except as specifically set forth herein. No supplement,
amendment, alteration, modification, waiver or termination of this Agreement
shall be binding unless executed in writing by the parties hereto.

17. Reform of Agreement. If any provision of this Agreement is, becomes or is
deemed invalid, illegal or unenforceable in any United States jurisdiction, such
provision shall be deemed amended to conform to applicable laws so as to be
valid and enforceable; or if it cannot be so amended without materially altering
the intention of the parties, it shall be stricken, and the remainder of this
Agreement shall remain in full force and effect.

18. Notices. Any notices, statements, payments, or reports required by this
Agreement shall be considered given if sent by United States Certified Mail,
postage prepaid and addressed as follows:

         If to CANCER CENTER:

                  Michael J. Best
                  Chief Financial Officer
                  The University of Texas M.D. Anderson Cancer Center
                  1515 Holcombe Blvd.
                  Houston, Texas  77030

         [*] Certain information on this page has been omitted and filed
             separately with the Commission. Confidential treatment has been
             requested with respect to the omitted portions.

                                       -4-
<PAGE>   5
         If to SPONSOR:

                  David Nance
                  Managing Partner
                  Texas Biomedical Development Partners
                  100 Congress Avenue, Suite 200
                  Austin, Texas  78701

19. Captions. The captions in this Agreement are for convenience only and shall
not be considered a part of or affect the construction or interpretation of any
provision of this Agreement.

20. Governing Law. This Agreement shall be governed and interpreted in
accordance with the substantive laws of the State of Texas and with applicable
laws of the United States of America.

                                       -5-
<PAGE>   6
         IN WITNESS WHEREOF, CANCER CENTER and SPONSOR entered into this
Agreement effective as of the date first hereinabove written and have executed
three (3) originals each of which are of equal dignity.

TEXAS BIOMEDICAL DEVELOPMENT           THE UNIVERSITY OF TEXAS
PARTNERS                               M.D. ANDERSON CANCER CENTER

By:  /s/ DAVID NANCE                   By  /s/ MICHAEL J. BEST
   -------------------------------       ---------------------------------
         David Nance                            Michael J. Best
         Managing Partner                       Chief Financial Officer

I have read this agreement
and understand my
obligations hereunder:                 CONTENT APPROVED:

By:  /s/ JACK A. ROTH                  By:  /s/ DONNA S. GILBERG
   -------------------------------       ---------------------------------
         Jack A. Roth, M.D.                     Donna S. Gilberg, CPA
         Principal Investigator                 Manager, Sponsored Agreements

                                       FORM APPROVED:

By:  /s/ CHARLES M. BALCH              By:  /s/ MATTHEW E. BURR
   -------------------------------       ---------------------------------
         Charles M. Balch, M.D.                 Matthew E. Burr, J.D.
         Head, Division of Surgery              Legal Services Officer

                                       -6-
<PAGE>   7
                               BUDGET FOR PROTOCOL

                                      [ * ]

          [*] Certain information on this page has been omitted and filed
              separately with the Commission. Confidential treatment has been
              requested with respect to the omitted portions.

                                       -7-
<PAGE>   8
                                 AMENDMENT NO. 1

                                       TO

                               RESEARCH AGREEMENT

         This Amendment No. 1 to Research Agreement ("AMENDMENT") is made and
entered into as of July 20, 1994 by and between INTRON THERAPEUTICS, INC., a
Delaware Corporation ("SPONSOR") and THE UNIVERSITY OF TEXAS M.D. ANDERSON
CANCER CENTER ("CANCER CENTER"), a component institution of the University of
Texas System ("SYSTEM").

                                    RECITALS

1. SPONSOR and CANCER CENTER entered into a SPONSORED RESEARCH AGREEMENT FOR
CLINICAL STUDY, number CS 93-27, dated as of February 11, 1993 (the "RESEARCH
AGREEMENT').

2. SPONSOR, CANCER CENTER and the Regents of the University of Texas System have
entered into a PATENT AND TECHNOLOGY LICENSE AGREEMENT dated as of July 20, 1994
(the "LICENSE AGREEMENT").

3. CANCER CENTER and SPONSOR wish to extend the term of the RESEARCH AGREEMENT,
acknowledge that the RESEARCH to be conducted thereunder will include matters
beyond the clinical trial protocol attached to the RESEARCH AGREEMENT as
originally executed, and that SPONSOR will have the option to include within the
LICENSED SUBJECT MATTER under the LICENSE AGREEMENT any intellectual property
that is made in the course of performing under the RESEARCH.

         NOW, THEREFORE, it is hereby agreed as follows:

         a. DEFINITIONS. Any capitalized terms that are not otherwise defined
herein shall be as in the RESEARCH AGREEMENT or the LICENSE AGREEMENT. In
addition, for all purposes of this AGREEMENT, the term "RESEARCH" shall be
deemed to include all work of CANCER CENTER personnel in performing the clinical
trial described int he protocol attached as Exhibit 1 and as modified from time
to time, as well as any work that is performed by Dr. Jack A. Roth or other
CANCER CENTER personnel comprising additional research projects described in
Attachment A-n, where n represents the ordinal number of a particular project.

         b. Invention and Patents. Section 3 of the RESEARCH AGREEMENT shall be
amended as follows:

                  1. So much of Section 3(a) of the RESEARCH AGREEMENT as reads
"(i) arises out of work performed pursuant to the obligations of this AGREEMENT'
is hereby amended to read "(i) arises out of the Research;".

                  2. Paragraph (b) of Section 3 is hereby deleted and replaced
in its entirety with the following:
<PAGE>   9
                  "b.      In the event that an Invention is made, CANCER CENTER
                           shall notify SPONSOR, which notice shall reference
                           this Section 3 and include a description of the
                           Invention in reasonable detail. SPONSOR shall have
                           the-option to include all worldwide patent rights
                           with respect to such Invention within the "EXISTING
                           PATENT RIGHTS" under Section 2.3(a) of the LICENSE
                           AGREEMENT," and to include related information,
                           know-how, biological materials and the like within
                           the TECHNOLOGY RIGHTS under the LICENSE AGREEMENT. To
                           exercise such option with respect to any particular
                           Invention, SPONSOR shall so notify CANCER CENTER
                           within 120 days after receipt of CANCER CENTER's
                           notice thereof as described above. Promptly following
                           such exercise, the parties shall revise Schedule A to
                           the LICENSE AGREEMENT to reflect the additional
                           patent applications so included. CANCER CENTER
                           warrants to SPONSOR that CANCER CENTER has the right
                           to grant to SPONSOR the option and rights
                           contemplated in this Section 3 and that upon exercise
                           of the option described herein with respect to any
                           Invention, all worldwide patent rights therein will
                           be included under the LICENSE AGREEMENT."

         c. Term. Section 14 of the RESEARCH AGREEMENT is hereby amended by
adding to the end thereof the following: "Following such initial Eighteen (18)
month period, unless earlier terminated as provided in Section 15, this
Agreement shall continue in full force and effect until terminated by either
party for any reason on ninety (90) days prior written notice to the other
party."

         d. Other. Except as expressly provided in this AMENDMENT, all other
terms, conditions and provisions of the RESEARCH AGREEMENT shall continue in
effect as provided therein.

         IN WITNESS WHEREOF, CANCER CENTER and SPONSOR entered into this
AMENDMENT effective as of the date first hereinabove written and have executed
three (3) originals each of which are of equal dignity.

                                       -2-
<PAGE>   10
         IN WITNESS WHEREOF, each of the parties has executed this Amendment as
of the date first above written.

TEXAS BIOMEDICAL DEVELOPMENT           THE UNIVERSITY OF TEXAS
PARTNERS                               M.D. ANDERSON CANCER CENTER

By:  /s/ DAVID NANCE                   By  /s/ MICHAEL J. BEST
   -------------------------------       ---------------------------------
         David Nance                            Michael J. Best
         Managing Partner                       Chief Financial Officer

I have read this agreement
and understand my
obligations hereunder:                 CONTENT APPROVED:

By:  /s/ JACK A. ROTH                  By:  /s/ DONNA S. GILBERG
   -------------------------------       ---------------------------------
         Jack A. Roth, M.D.                     Donna S. Gilberg, CPA
         Principal Investigator                 Manager, Sponsored Agreements

                                       FORM APPROVED:

By:  /s/ HELMUTH GOEPFERT              By:      Not applicable
   -------------------------------       ---------------------------------
         Helmuth Goepfert, M.D.                 Matthew E. Burr, J.D.
         Head, Division of Surgery and          Legal Services Officer
         Anesthesiology (Ad interim)

                                       -3-
<PAGE>   11
                                    EXHIBIT 1

                                    PROTOCOL

                                      [*]

         [*] Certain information on this page has been omitted and filed
             separately with the Commission. Confidential treatment has been
             requested with respect to the omitted portions.

                                       -4-
<PAGE>   12
                                 AMENDMENT NO. 2

                                       TO

                            CLINICAL STUDY AGREEMENT

STATE OF TEXAS
COUNTY OF HARRIS

         AMENDMENT, effective this 1st day of January, 1995, between THE
UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (hereinafter referred to
as"CANCER CENTER"), a component of THE UNIVERSITY OF TEXAS SYSTEM (hereinafter
referred to as "SYSTEM") located at Houston, Texas, and INTROGEN THERAPEUTICS,
formerly Intron Therapeutics, Inc. (hereinafter referred to as "SPONSOR"), of
the Clinical Study Agreement made by these parties and dated the 11th day of
February, 1993 and amended the 20th day of July, 1994, regarding research on the
evaluation and study of the "Clinical Protocol for Modification of Tumor
Supressor Gene Expression in Non-Small Cell Lung Cancer with a Retroviral Vector
Expressing Wildtype (normal) p53).

1. CANCER CENTER and SPONSOR agree that the period of work identified in the
original Clinical Study Agreement shall be extended to the later of February 29,
1996 or the completion of the project.

2. CANCER CENTER and SPONSOR agree that the work to be done during this extended
work period will be performed according to the procedures described in the
revised workscope, the title of which is "Clinical Protocol for Modification of
Tumor Supressor Gene Expression in Non-Small Cell Lung Cancer with a Retroviral
Vector Expressing Wildtype (normal) p53", a copy of which is attached hereto as
Exhibit I and incorporated herein by reference. The workscope has been amended
and approved in accordance with institutional policy. The Clinical Study
Agreement may be extended by the SPONSOR upon notification to CANCER CENTER and
Investigator to provide CANCER CENTER and Investigator with the funds needed to
complete the research provided the research is within the workscope as herein
described.

3. CANCER CENTER and SPONSOR agree that the specific additional costs associated
with this work [ * ].

4. SPONSOR and CANCER CENTER agree that payment of amounts by SPONSOR shall be
made [ * ].

         OTHERWISE, the terms and provisions of the original Agreement executed
on the 11th day of February, 1993 and amended on the 20th day of July, 1994 by
and between the parties hereto shall remain in full force and effect, provided,
however, that in the event of a conflict in the terms and conditions between
this Amendment No. 2 and the Clinical Study Agreement, the terms and conditions
of this Amendment shall prevail.

         [*] Certain information on this page has been omitted and filed
             separately with the Commission. Confidential treatment has been
             requested with respect to the omitted portions.
<PAGE>   13
         IN WITNESS WHEREOF, the parties have executed two (2) original
counterparts of this Amendment No. 2, each of which are of equal dignity and
effective as of the date first hereinabove written.

INTROGEN THERAPEUTICS                  THE UNIVERSITY OF TEXAS
                                       M.D. ANDERSON CANCER CENTER

By:  /s/ DAVID NANCE                   By  /s/ DONNA S. GILBERG
   -------------------------------       ----------------------------------
         David Nance                            Donna S. Gilberg, CPA
         President                              Manager, Sponsored Programs

Date:    6/24/95                       Date:  6/22/95
     -----------------------------          -------------------------------

                                       I have read this agreement and
                                       understand my obligations hereunder:

                                       By:  /s/ JACK A. ROTH
                                         ----------------------------------
                                                Jack A. Roth, M.D.
                                                Principal Investigator

                                       By:  /s/ HELMUTH GOEPFERT
                                         ----------------------------------
                                                Helmuth Goepfert, M.D.
                                                Ad Interim Head, Div. of Surgery

Payment Mailing Address:

The University of Texas
M.D. Anderson Cancer Center
Attn.:  Manager, Sponsored Programs
P.O. Box 297402
Houston, Texas  77297
Tax ID:  74-6001118-A1

                                       -2-
<PAGE>   14
                                    EXHIBIT 2

                                     BUDGET

                                      [ * ]

         [*] Certain information on this page has been omitted and filed
             separately with the Commission. Confidential treatment has been
             requested with respect to the omitted portions.

                                       -3-
<PAGE>   15
                                 AMENDMENT NO. 3

                                       TO

                            CLINICAL STUDY AGREEMENT

         AMENDMENT, effective this 31st day of December, 1995, between THE
UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (hereinafter referred to as
"CANCER CENTER"), a component of THE UNIVERSITY OF TEXAS SYSTEM (hereinafter
referred to as "SYSTEM") located at Houston, Texas, and INTROGEN THERAPEUTICS
(hereinafter referred to as "SPONSOR"), of the Sponsored Research Agreement made
by these parties and dated the 11th day of February, 1993 and subsequently
amended, regarding research on the evaluation and study of the tumor suppressor
gene expression in non-small cell lung cancer.

1. CANCER CENTER and SPONSOR agree that the period of work identified in the
original Clinical Study Agreement shall be extended to December 31, 1996.
Thereafter, this Agreement can be extended for additional annual periods upon
the mutual written consent of CANCER CENTER and SPONSOR.

2. CANCER CENTER and SPONSOR agree that the work to be done during this extended
work period will be performed according to the procedures described in the
additional Protocol, the title of which is "Modification of Tumor Suppressor
Gene Expression and Induction of Apoptosis in Non-Small Cell Lung Cancer (NSCLC)
with an Adenovirus Vector Expressing Wildtype p53 and Cisplatin," a copy of
which is attached hereto as Exhibit I and incorporated herein by reference. The
Protocol has been approved in Accordance with institutional policy.

3. Award. During the term of this Amendment as set forth herein and in
consideration for CANCER CENTER's performance of the Protocol, SPONSOR agrees to
pay CANCER CENTER a fee [ * ].

4. ACCESS TO INFORMATION. All results of and information arising from the
Research shall be made available and accessible to SPONSOR by CANCER CENTER.
SPONSOR shall have the right to obtain copies or duplicates of such results and
information on a timely basis, in either written or electronic form, upon
SPONSOR giving CANCER CENTER reasonable notice of SPONSOR's desire to obtain
such results and information.

         OTHERWISE the terms and provisions of the original Agreement executed
on the 11th day of February, 1993 and subsequently amended by and between the
parties hereto shall remain in full force and effect, provided, however, that in
the event of a conflict in the terms and conditions between this Amendment No. 3
and the Clinical Study Agreement, the terms and conditions of this Amendment
shall prevail.

         [*] Certain information on this page has been omitted and filed
             separately with the Commission. Confidential treatment has been
             requested with respect to the omitted portions.
<PAGE>   16
         IN WITNESS WHEREOF, the parties have executed two (2) original
counterparts of this Amendment No. 3, each of which are of equal dignity and
effective as of the date first hereinabove written.

INTROGEN THERAPEUTICS                  THE UNIVERSITY OF TEXAS
                                       M.D. ANDERSON CANCER CENTER

By:  /s/ DAVID NANCE                   By  /s/ DONNA S. GILBERG
   -------------------------------       ----------------------------------
         David Nance                            Donna S. Gilberg, CPA
         President                              Manager, Sponsored Programs

Date:    12/28/95                       Date: 12/31/95
     -----------------------------          -------------------------------

                                       I have read this agreement and
                                       understand my obligations hereunder:

                                       By:  /s/ JACK A. ROTH
                                         ----------------------------------
                                                Jack A. Roth, M.D.
                                                Principal Investigator

                                       By:  /s/ HELMUTH GOEPFERT
                                         ----------------------------------
                                                Helmuth Goepfert, M.D.
                                                Ad Interim Head, Div. of Surgery

Payment Mailing Address:

The University of Texas
M.D. Anderson Cancer Center
Attn.:  Manager, Sponsored Programs
P.O. Box 297402
Houston, Texas  77297
Tax ID:  74-6001118-A1

                                       -2-
<PAGE>   17
                                    PROTOCOL

                                      [ * ]

              THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER

                                INFORMED CONSENT

Protocol Title:   Clinical Protocol for Modification of Tumor Suppressor Gene
                  Expression in Non-Small Cell Lung Cancer (NSCLC) with a
                  Retroviral Vector Expressing Wildtype (normal) p53

1.
     ---------------------           -----------------
     Participant's Name                 I.D. Number

You have the right to know about the procedures that are to be used in your
participation in clinical research so as to afford you an opportunity to make
the decision whether or not to undergo the procedure after knowing the risks
and hazards involved. This disclosure is not meant to frighten or alarm you; it
is simply an effort to make you better informed so that you may give or
withhold your consent to participate in clinical research. This informed
consent does not supersede other consents you may have signed.

DESCRIPTION OF RESEARCH

2.   PURPOSE OF THE STUDY: Some lung cancers seem to arise because problems
     occur in a part of the cells (a particular gene called "p53") that usually
     stops cancer. In this clinical research study the investigators are trying
     to insert a normal copy of the p53 gene into the lung cancer cells to see
     if this will cause the cancer cells to stop growing. As a "vector", that
     is, as a vehicle to get the p53 gene into the cells, the investigators will
     use a retrovirus (a modified leukemia virus) that has been altered so it
     cannot reproduce itself. Because the investigators are at an early stage in
     the research, the investigators do not expect to cure the patients who
     participate; instead, the immediate purpose of the study is to find out
     what dose of vector can be used without harming patients and whether the
     introduced p53 genes will cause cancer cells to stop growing.

3.   DESCRIPTION OF RESEARCH: The experimental protocol is as follows: Patients
     for this study will be selected from among patients with non-small cell
     lung cancer who are not now candidates for radiation therapy or surgery.
     Patients with local tumors that cannot be removed with surgery or have
     recurred after radiation can participate. It is not necessary that the
     patient received chemotherapy (drugs) alone but-chemotherapy may be an
     alternative treatment. These tumors will be directly injected with the
     retrovirus. Patients who have known tumors within their airway can also
     participate. These patients are scheduled to have bronchoscopic exams as
     part of their evaluation under either local anesthesia or general
     anesthesia. The surgeon performs an examination using a regular white light
     source to illuminate the tracheobronchial tree. If a tumor is found that is
     obstructing a

                                                                         [STAMP]

[*] Certain information on this page has been omitted and filed separately with
    the Commission. Confidential treatment has been requested with respect to
    the omitted portions.

                                      -3-

<PAGE>   18

     portion of the tracheobronchial tree, that patient will be considered
     eligible for the study. It must also be possible to reduce the number of
     tumor cells to a small amount, with removal through the bronchoscope or
     laser treatment. Costs directly related to this research will not be the
     responsibility of the patient. These costs will be the responsibility of
     the sponsor of this research.

     The tumor must have a specific gene mutation in it. It may be possible to
     find this mutation in specimens from previous biopsies. However, if these
     are not available, new biopsies must be performed. If the new biopsy
     material does not show the mutation, the patient cannot participate in the
     study. The residual tumor will be injected daily for 5 consecutive days
     with a retrovirus containing a gene that may be able to correct an
     abnormality detected in the cancer cells. This treatment may be repeated in
     three months as long as there is evidence that the tumor is not growing and
     that the treatment appears safe. The cost of the routine bronchoscopy and
     biopsies which are part of the work up of patient's condition shall be
     his/her responsibility. A maximum of 14 patients will be entered in the
     study.

     The investigators wish to follow the patient's medical condition for the
     rest of the patient's life. If the patient should move, the patient should
     notify Dr. Roth's office.

     PERMISSION FOR AUTOPSY: In case of death, the family of the patient will be
     asked for an autopsy because an accurate documentation of the precise cause
     of death may be important to all future patients.

4.   RISKS, SIDE EFFECTS AND DISCOMFORTS TO PARTICIPANTS

     A few additional biopsies will be required. A bronchoscopic biopsy samples
     a very tiny piece of the mucosa inside the lung. Risks of biopsies include
     hemoptysis (coughing up blood), which is usually transient and self
     limited. Severe hemorrhage requiring emergency maneuvers such as intubation
     and thoracotomy is exceedingly rare. Although extremely rare, any
     experimental procedure may result in unforeseen risks. Appropriate medical
     therapy will be made available for the treatment of such side effects.

     4a. This clinical procedure may involve unforeseeable risks to unborn
         children, therefore, the participants should practice adequate methods
         of birth control throughout the period of their involvement in the
         clinical study if they are sexually active. To help prevent injury to
         children, the female participants should refrain from breast feeding
         during participation in the clinical research study.

     4b. Possibility of Causing a New Cancer. It is possible that the research
         could cause cancer in normal cells but the investigators believe the

                                      -4-
<PAGE>   19

         risk is very small particularly because the investigators test the
         material that is injected to make sure it does not contain
         disease-causing viruses.

         Risk from murine retrovirus. The retrovirus derived from the Moloney
         murine leukemia virus is modified so that it no longer contains intact
         viral genes. Thus it cannot produce an intact infectious virus.
         Therefore, the risk of getting a virus infection is extremely low.

     4c. A small amount of protamine is added to the retroviral mixture.
         Infrequent allergic reactions and low blood pressure have occurred as
         side-effects when this drug is given. These are very unlikely to occur
         with the small dose given.

5.   POTENTIAL BENEFITS: The primary purposes of this study are scientific,
     namely, to test the safety of the procedure and to see whether the injected
     gene will function in the cancer cells. If this happens, there might be a
     potential therapeutic benefit to subjects, depending on how much of their
     cancer is destroyed. It is possible that injection of the retrovirus will
     slow the growth of the tumor and prevent further blockage of the lung. The
     main benefit expected is advancing knowledge and developing future studies
     and treatments rather than curing the patient-subjects who participate in
     this study, although that is always a possibility.

6.   ALTERNATE PROCEDURES OR TREATMENTS: Patients will be eligible for this
     study if conventional therapy such as surgery or external beam radiation
     therapy has already been performed or cannot be done.

UNDERSTANDING OF PARTICIPANTS

7.   I have been given an opportunity to ask any question concerning the
     procedure involved and the investigator has been willing to reply to my
     inquiries. This procedure will be administered under the above numbered,
     titled and described clinical research protocol at this institution. I
     hereby authorize Dr. Jack A. Roth, the attending physician/investigator,
     and designated associates to administer the treatment.

8.   I have been told and understand that my participation in this clinical
     research study is voluntary. I may decide not to participate, or withdraw
     my consent and discontinue my participation at any time. Such action will
     be without prejudice and there shall be no penalty or loss of benefits to
     which I may otherwise be entitled, and I will continue to receive treatment
     by my physician at this institution.

     Should I decide not to participate or withdraw my consent from
     participation in this clinical research, I have been advised that I should
     discuss the

                                                                         [STAMP]

                                      -5-
<PAGE>   20

     consequences or effects of my decision with my physician.

     In addition, I understand that the investigator may discontinue the
     clinical research study if, in the sole opinion and discretion of the
     investigator, the study or treatment offers me little or no future benefit,
     or the supply of medication ceases to be available or other causes prevent
     continuation of the clinical research study. The investigator will notify
     me should such circumstances arise and my physician will advise me about
     available treatments which may be of benefit at that time.

     I will be informed of any new findings developed during the course of this
     clinical research study which might be relevant to my willingness to
     continue participation in the study.

9.   I have been assured that confidentiality will be preserved, except that
     qualified monitors from Microbiological Associates, Inc., the Food and Drug
     Administration, or National Cancer Institute may review my records where
     appropriate and necessary. Qualified monitors shall include assignees
     authorized by the Surveillance Committee of this institution provided that
     confidentiality is assured and preserved. My name will not be revealed in
     any reports or publications resulting from this study without my expressed
     consent.

10.  I have been informed that, should I suffer any injury as a result of
     participation in this research activity, reasonable medical facilities are
     available for treatment at this institution. I understand, however, that I
     cannot expect to receive any credit or reimbursement for expenses from this
     institution or any financial compensation from this institution for such
     injury.

11.  I have been informed that I should inquire of the attending physician
     whether or not there are any services, investigational agents or devices,
     and/or medications being offered by the sponsor of this clinical research
     project at a reduced cost or without cost.

     Costs related to my medical care, including expensive tests or procedures
     that may be required by this clinical research study, shall be my
     responsibility unless the sponsor or other agencies contribute toward said
     costs. Clarification of specific cost issues may be addressed in section 3
     of this informed consent. I have been given the opportunity to discuss the
     expenses or costs associated with my participation in this research
     activity.

12.  It is possible that this research project will result in the development of
     beneficial treatments, devices, new drugs, or possible patentable
     procedures, in which event I understand that I cannot expect to receive any
     compensation or benefits from the subsequent use of information acquired
     and development through my participation in this research project.

                                      -6-
<PAGE>   21

13.  I understand that refraining from breast feeding and practicing effective
     contraception is medically necessary and a prerequisite for my
     participation in this clinical research study. Should contraception be
     interrupted or if there is any suspicion of pregnancy, my participation in
     this clinical research study will be terminated at the sole discretion of
     the investigator.

14.  I may discuss any questions or problems during or after this study with
     Dr. Jack A. Roth at (713) 792-6932. In addition, I may discuss any
     problems I may have or any questions regarding my rights during or after
     this study with the Chairman or the Surveillance Committee at
     (713) 792-3220 and may in the event any problem arises during this clinical
     research contact the parties named above.

CONSENT

Based upon the above, I consent to participate in the research and have
received a copy of the consent form.

-------------------------               ---------------------------
DATE                                    SIGNATURE OF PARTICIPANT

-------------------------               ---------------------------
WITNESS OTHER THAN PHYSICIAN            SIGNATURE OF PERSON
OR INVESTIGATOR                         RESPONSIBLE & RELATIONSHIP

I have discussed this clinical research study with the Participant and/or his
or her authorized representative using language which is understandable and
appropriate. I believe that I have fully informed this participant of the
nature of this study and its possible benefits and risks, and I believe the
participant understood this explanation.

                                   --------------------------------
                                   PHYSICIAN/INVESTIGATOR

                                                                [STAMP]

                                      -7-<PAGE>   1
                                                                  Exhibit 10.11

SR 93-04

                          SPONSORED RESEARCH AGREEMENT

         Agreement, made this 11th day of February, 1993, by and by and between
THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (hereinafter referred to as
"CANCER CENTER"), a component institution of The University of Texas System
(hereinafter referred to as "SYSTEM"), located in Houston, Texas, and Texas
Biomedical Development Partners (hereinafter referred to as "SPONSOR"), located
in Austin, Texas.

                                   WITNESSETH:

         WHEREAS, CANCER CENTER has research facilities and situations which
would allow investigation and study of the "Development of Therapeutic Treatment
and Prevention of Lung Cancer" an described in Exhibit I hereinafter referred to
as ("Research"), a copy of which in attached hereto and incorporated herein by
reference; and

         WHEREAS, both SPONSOR and CANCER CENTER consider it necessary and
desirable to perform the Research;

         NOW, THEREFORE , the parties agree as follows:

         1. Evaluation. SPONSOR agrees to engage the services of CANCER CENTER
as an independent contractor to perform the Research. The Research will be under
the supervision of Jack A. Roth, M.D. (Principal Investigator) at CANCER CENTER,
with the assistance of appropriate associates and colleagues at CANCER CENTER as
may be required.

         2. Research. CANCER CENTER agrees as an independent contractor to
conduct the Research. Such Research was originally approved by CANCER CENTER in
accordance with CANCER CENTER policy and may be subsequently amended only in
accordance with CANCER CENTER policy and the written agreement of CANCER CENTER
and SPONSOR as provided for in Article 15 herein below.

         3. Invention and Patents.

                  a. For all purposes herein, "Invention" shall mean any
discovery, concept or idea whether or not patentable or copyrightable, which (i)
arises out of work performed pursuant to the obligations of this Agreement; (ii)
is conceived and reduced to practice during the term of the Agreement as defined
in Article 13 herein below; and (iii) includes but is not limited to processes,
methods, software, formula, techniques, compositions of matter, devices, and
improvements thereof and know-how relating thereto. Inventions made solely by
the Principal investigator and/or other CANCER CENTER personnel
 as identified in Article I hereinabove or agents of CANCER CENTER shall be the
sole property of CANCER CENTER.

<PAGE>   2

                  b. In the event that an invention is made, CANCER CENTER
agrees to include such invention in the option Agreement of December 17, 1992
(attached hereto as Exhibit II) previously entered into by CANCER CENTER and
SPONSOR and give notice of such Invention to SPONSOR within thirty (30) days of
the identification of such Invention.

         4. Confidentiality. In the course of work performed pursuant to the
Research under this Agreement, should either party provide confidential
information to the other party, the recipient party shall, until three (3) years
after the termination of this Agreement, maintain the confidentiality of that
information as it maintains the confidentiality of its own confidential
information, and shall not disclose such confidential information to any other
party, nor shall the recipient party disclose the disclosing party's
confidential information to the recipient's employees other than those employees
having a "need-to-know". Confidential information shall be clearly marked as
such. If disclosed orally, the party making the disclosure shall be responsible
for clearly informing the recipient party of the confidentiality of the
information disclosed. Notwithstanding the other provisions of this paragraph,
nothing disclosed hereunder shall be construed as confidential information
which:

                  a. is or becomes available to the public (except by a breach
of this Agreement by a party hereto);

                  b. is rightfully received from another party not under
obligation of confidentiality to the disclosing party;

                  c. is not known by the recipient party, or is independently
developed by the recipient party by persons without access to the confidential
information;

                  d. is approved for release by the party designating the
information an confidential;

                  e. is not identified as confidential at the time of
disclosure;

                  f. is not in writing or physical form at time of disclosure or
reduced to a written or physical form and identified as confidential within
thirty (30) days of disclosure; or

                  g. is required to be disclosed under the laws of the United
States of America or the State of Texas or other governmental bodies, provided
that the parties shall first exhaust all reasonable measures available to
protect the confidentiality of such information upon disclosure.

         5. Publication Rights. Notwithstanding the provisions of Article 4 of
this Agreement, CANCER CENTER may publish scientific papers relating to the
collaborative research performed under this Agreement. In the event that CANCER
CENTER wishes to publish, CANCER CENTER shall notify SPONSOR of its desire to
publish [*] in advance of publication and shall furnish to SPONSOR a written
description of the subject matter of the publication in order to permit SPONSOR
to review and comment thereon.

         [*]    Certain information on this page has been omitted and filed
                separately with the Commission. Confidential treatment has been
                requested with respect to the omitted portions.

                                       -2-

<PAGE>   3

         6. Publicity. CANCER CENTER acknowledges SPONSOR's intention to
distribute periodically informational releases and announcements to the news
media regarding the progress of research hereunder. SPONSOR shall not release
such materials containing the name of CANCER CENTER or any of its employees
without prior written approval by an authorized representative of CANCER CENTER,
and said approval shall not be unreasonably withheld. Should CANCER CENTER
reject the news release, CANCER CENTER and SPONSOR agree to discuss the reasons
for CANCER CENTER's rejection, and every effort shall be made to develop an
appropriate informational news release within the bounds of accepted academic
practices. SPONSOR reserves the same right in the event that CANCER CENTER
desires to distribute a news release concerning the research program. Nothing
herein shall be construed as prohibiting CANCER CENTER or SPONSOR from reporting
on this study to a governmental agency.

         7. Responsibility. The parties each agree to assume individual
responsibility for the actions and omissions of their respective employees,
agents and assigns in conjunction with this evaluation.

         8. Independent Contractor. SPONSOR will not have the right to direct or
control the activities of CANCER CENTER in performing the services provided
herein, and CANCER CENTER shall perform services hereunder only as an
independent contractor, and nothing herein contained shall be construed to be
inconsistent with this relationship or status. Under no circumstances shall
CANCER CENTER be considered to be an employee or agent of SPONSOR. This
Agreement shall not constitute, create or in any way be interpreted as a joint
venture, partnership or formal business organization of any kind.

         9. Title to Equipment. CANCER CENTER shall retain title to all
equipment purchased and/or fabricated by it with funds provided by SPONSOR under
this Agreement.

         10. Survivorship. The provisions of Article 3, 4, 5, 6, and 12 shall
survive any expiration or termination of this Agreement.

         11. Assignment. This Agreement may not be assigned by either party
without the prior written consent of the other party; provided, however, that
SPONSOR may assign this Agreement to any purchaser or transferee of all or
substantially all of SPONSOR's business upon prior written notice to CANCER
CENTER.

         12. Indemnification. CANCER CENTER shall, to the extent authorized
under the Constitution and the laws of the State of Texas, hold SPONSOR harmless
from liability resulting from the negligent acts or omissions of CANCER CENTER,
its agents or employees pertaining to the activities to be carried out pursuant
to the obligations of this Agreement; provided, however, that CANCER CENTER
shall not hold SPONSOR harmless from claims arising out of the negligence of
SPONSOR, its officers, agents or any person or entity not subject to CANCER
CENTER supervision or control.

         SPONSOR shall indemnify and hold harmless SYSTEM, CANCER CENTER, their
regents, officers, agents and employees from any liability or loss resulting
from judgments or claims against them arising out of the activities to be
carried out pursuant to the obligations of this Agreement or the use by

                                       -3-

<PAGE>   4

SPONSOR of the results of the Research, provided, however, that the following is
excluded from SPONSOR's obligation to indemnify and hold harmless:

                  a.       the negligent failure of CANCER CENTER to comply with
                           any applicable governmental requirements; or

                  b.       the negligence or willful malfeasance by a regent,
                           officer, agent or employee of CANCER CENTER or
                           SYSTEM.

         13. Award. SPONSOR agrees to pay CANCER CENTER a fee of Three Hundred
Thousand and No/100 Dollars ($300,000.00) for expenses and other related costs
incurred in conjunction with the Research. This fee, as shown by approximate
category of expense in Exhibit 1, which is attached hereto and is incorporated
herein by reference, for information only, shall be payable in Four (4) equal
installments of Seventy-Five Thousand and No/100 Dollars ($75,000.00) each by
SPONSOR to CANCER CENTER. The first such installment shall be due within thirty
(30) days of the date of execution of this Agreement. The subsequent
installments shall be due and payable as follows: (a) three (3) months after
execution, (b) six (6) months after execution and (c) nine (9) months after
execution.

         14. Basic Term. This Agreement shall become effective as of the date
first herein above written and unless earlier terminated as hereinafter
provided, shall continue in force for a period of Eighteen (18) months after the
same.

         15. Default and Termination. In the event that either party to this
Agreement shall be in default of any of its material obligations hereunder and
shall fail to remedy such default within [*] after receipt of written notice
thereof, the party not in default shall have the option of terminating this
Agreement by giving written notice thereof, notwithstanding anything to the
contrary contained in this Agreement. Termination of this Agreement shall not
affect the rights and obligations of the parties which accrued prior to the
effective date of termination. SPONSOR shall pay CANCER CENTER for all
reasonable expenses Incurred or committed to be expanded as of the effective
termination date, subject to the maximum amount as specified in Article 13.

         16. Entire Agreement. The parties acknowledge that this Agreement and
the attached Exhibits hereto represent the sole and entire Agreement between the
parties hereto pertaining to the Research and that such supersedes all prior
Agreements, understandings, negotiations and discussions between the parties
regarding same, whether oral or written. There are no warranties,
representations or other Agreements between the parties in connection with the
subject matter hereof except as specifically set forth herein. No supplement,
amendment, alteration, modification, waiver or termination of this Agreement
shall be binding unless executed in writing by the parties hereto.

         17. Reform of Agreement. If any provision of this Agreement is, or in
doomed invalid, illegal or unenforceable in any United States jurisdiction, such
provision shall be deemed amended to conform to applicable laws so as to be
valid and enforceable; or if it cannot be so amended without materially altering
the Intention of the parties, it shall be stricken, and the remainder of this
Agreement shall remain in full force and affect.

         [*]    Certain information on this page has been omitted and filed
                separately with the Commission. Confidential treatment has been
                requested with respect to the omitted portions.

                                       -4-

<PAGE>   5

         18. Default and Termination. Any notices, statements, payments, or
reports by this Agreement shall be considered given if sent by United States
Certified Mail, postage prepaid and addressed as follows:

         If to CANCER CENTER:

         Michael J. Sent
         Chief Financial officer

         The University of Texas M.D. Anderson Cancer Center 1515 Holcombe Blvd.
         Houston, Texas  77030

         If to SPONSOR

         David Nance
         Managing Partner
         Texas Biomedical Development Partners
         100 Congress Avenue, Suite 200 Austin, Texas  78701

         19. Caption. The captions in this Agreement are for convenience only
and shall not be considered a part of or affect the construction or
interpretation of any provision of this Agreement.

         20. Governing Law. This Agreement shall be governed and interpreted in
accordance with the substantive laws of the State of Texas and with applicable
laws of the United States of America.

                                       -5-

<PAGE>   6

         IN WITNESS WHEREOF, CANCER CENTER and SPONSOR entered into this
Agreement effective as of the date first herein above written and have executed
three (3) originals each of which are of equal dignity.

TEXAS BIOMEDICAL DEVELOPMENT                   THE UNIVERSITY TEXAS
PARTNERS                                       M.D. ANDERSON CANCER CENTER

By:/s/ DAVID NANCE                             By:/s/MICHAEL J. BEST
---------------------------------------           ------------------------------
     David Nance                                   Michael J. Best
     Managing Partner                              Chief Financial Officer

I have read this agreement and
understanding my obligations hereunder:        CONTENT APPROVED:

By:/s/ JACK A. ROTH                            By:/s/ DONNA S. GILBERG
---------------------------------------           ------------------------------
     Jack A. Roth, M.D.                            Donna S. Gilberg, CPA
     Principal Investor                            Manager, Sponsored Agreements

                                               FORM APPROVED:

By:/s/ CHARLES M. BALCH                        By:/s/ MATTHEW E. BURR
---------------------------------------           ------------------------------
     Charles M. Balch, M.D.                        Matthew E. Burr, J.D.
     Head, Division of Surgery                     Legal Services Officer

                                       -6-

<PAGE>   7

                                    EXHIBIT I

                                       [*]

     [*]   Certain information on this page has been omitted and filed
            separately with the Commission. Confidential treatment has been
            requested with respect to the omitted portions.
<PAGE>   8

                                 AMENDMENT NO. 1

                                       TO

                               RESEARCH AGREEMENT

         This Amendment No. 1 to Research Agreement ("AMENDMENT") is made and
entered into as of July 20, 1994 by and between INTRON THERAPEUTICS, INC., a
Delaware Corporation ("SPONSOR") and THE UNIVERSITY OF TEXAS M.D. ANDERSON
CANCER CENTER ("CANCER CENTER"), a component institution of the University of
Texas System ("SYSTEM").

                                    RECITALS

         A. SPONSOR and CANCER CENTER entered into a SPONSORED RESEARCH
AGREEMENT, number SR 93-04, dated as of February 11, 1993 (the "RESEARCH
AGREEMENT").

         B. SPONSOR, CANCER CENTER and the Regents of the University of Texas
System have entered into a PATENT AND TECHNOLOGY LICENSE AGREEMENT dated as of
July 20, 1994 (the "LICENSE AGREEMENT").

         C. CANCER CENTER and SPONSOR wish to extend the term of the RESEARCH
AGREEMENT, acknowledge that the RESEARCH to be conducted thereunder will include
matters beyond the study outline attached to the RESEARCH AGREEMENT as
originally executed, and that SPONSOR will have the option to include within the
LICENSED SUBJECT MATTER under the LICENSE AGREEMENT any intellectual property
that is made in the course of performing under the RESEARCH.

         NOW, THEREFORE, it is hereby agreed as follows:

                  21. DEFINITIONS. Any capitalized terms that are not otherwise
defined herein shall be defined in the RESEARCH AGREEMENT or the LICENSE
AGREEMENT. In addition, for all purposes of the RESEARCH AGREEMENT, the term
"RESEARCH" shall be deemed to include all work of CANCER CENTER personnel in
performing the study described in Exhibit I to RESEARCH AGREEMENT as originally
executed and as modified from time to time, as well as any work that is
performed by Dr. Jack A. Roth or other CANCER CENTER personnel comprising
additional research projects described in Attachment A-n, where n represents the
ordinal number of a particular project.

                  22. Invention and Patents. Section 3 of the RESEARCH AGREEMENT
shall be amended as follows:

                           (a) So much of Section 3(a) of the RESEARCH AGREEMENT
as reads "(i) arises out of work performed pursuant to the obligations of this
AGREEMENT' is hereby amended to read "(i) arises out of the Research;"

<PAGE>   9

                           (b) Paragraph (b) of Section 3 is hereby deleted and
replaced in its entirety with the following:

                  "b.      In the event that an Invention is made, CANCER CENTER
                           shall notify SPONSOR, which notice shall reference
                           this Section 3 and include a description of the
                           Invention in reasonable detail. SPONSOR shall have
                           the option to include all worldwide patent rights
                           with respect to such Invention within the "EXISTING
                           PATENT RIGHTS" under Section 2.3(a) of the LICENSE
                           AGREEMENT,' and to include related information,
                           know-how, biological materials and the like within
                           the TECHNOLOGY RIGHTS under the LICENSE AGREEMENT. To
                           exercise such option with respect to any particular
                           Invention, SPONSOR shall so notify CANCER CENTER
                           within 120 days after receipt of CANCER CENTER's
                           notice thereof as described above. Promptly following
                           such exercise, the parties shall revise Schedule A to
                           the LICENSE AGREEMENT to reflect the additional paten
                           applications so included. CANCER CENTER warrants to
                           SPONSOR that CANCER CENTER has the right to grant to
                           SPONSOR the option and rights contemplated in this
                           Section 3 and that upon exercise of the option
                           described herein with respect to any Invention, all
                           worldwide patent rights therein will be included
                           under the LICENSE AGREEMENT.'

                  23. Term. Section 14 of the RESEARCH AGREEMENT is hereby
amended by adding to the end thereof the following: "Following such initial
Eighteen (18) month period, unless earlier terminated as provided in Section 15,
this Agreement shall continue in full force and effect until terminated by
either parry for any reason on ninety (90) days prior written notice to the
other party."

                  24. Other. Except as expressly provided in this AMENDMENT, all
other terms, conditions and provisions of the RESEARCH AGREEMENT shall continue
in effect as provided therein.

         IN WITNESS WHEREOF, CANCER CENTER and SPONSOR entered into this
AMENDMENT effective as of the date first hereinabove written and have executed
(3) originals each of which are of equal dignity.

                                       -2-

<PAGE>   10

         IN WITNESS WHEREOF, each of the parties has executed this Amendment as
of the date first above written.

TEXAS BIOMEDICAL DEVELOPMENT                        THE UNIVERSITY OF TEXAS
PARTNERS                                            M.D. ANDERSON CANCER CENTER

By:/s/ DAVID NANCE                                  By:/s/ MICHAEL J. BEST
-----------------------------------                    -------------------------
     David Nance                                        Michael J. Best
     Managing Partner                                   Chief Financial Officer

I have read this agreement and
understand my obligations
hereunder:                                          CONTENT APPROVED:

By:/s/ JACK A. ROTH                                 By:/s/ DONNA S. GILBERG
-----------------------------------                    -------------------------
     Jack A. Roth, M.D.                                 Donna S. Gilberg, CPA
     Principal Investor                                 Manager, Sponsored
                                                             Agreements

                                                    FORM APPROVED:

By:/s/ HELMUTH GOEFERT                              By:NOT APPLICABLE
-----------------------------------                    -------------------------
     Helmuth Goefert, M.D.                              Matthew E. Burr, J.D.
     Head, Division of                                  Legal Services Officer
     Surgery and Anesthesiology
     (Ad interim)

                                       -3-

<PAGE>   11

                                 AMENDMENT NO. 2

                                       TO

                          SPONSORED RESEARCH AGREEMENT

STATE OF TEXAS
COUNTY OF HARRIS

         AMENDMENT, effective this 1st day of January, 1995, between THE
UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (hereinafter referred to as
"CANCER CENTER"), a component of THE UNIVERSITY OF TEXAS SYSTEM (hereinafter
referred to as "SYSTEM") located at Houston, Texas, and INTROGEN THERAPEUTICS,
formerly Intron Therapeutics, Inc. ((hereinafter referred to as "SPONSOR"), of
the Sponsored Research Agreement made by these parties and dated the 11th day of
February, 1993 and amended the 20th day of July, 199_, regarding research on the
evaluation and study of the "Development of Therapeutic Treatment and
Prevention of Lung Cancer".

         1.       CANCER CENTER and SPONSOR agree that the period of work
                  identified the original Sponsored Research Agreement shall be
                  extended to the latter of February 29, 1996 or the completion
                  of the project.

         2.       CANCER CENTER and SPONSOR agree that the work to be done
                  during this extended work period will be performed according
                  to the procedures described in the revised workscope, the
                  title of which is "Development of Gene Therapeutic Treatment
                  and Prevention for Cancer", a copy of which is attached hereto
                  as Exhibit I and incorporated herein by reference. The
                  workscope has been amended and approved in accordance with
                  institutional policy. The sponsored research agreement may be
                  extended by the Sponsor upon notification to CANCER CENTER and
                  Investigator to provide CANCER CENTER and Investigator with
                  the funds needed to complete the research provided the
                  research is within the workscope as herein described.

         3.       CANCER CENTER and SPONSOR agree that the specific additional
                  costs associated with this work shall be One Million Nine
                  Hundred Eight Thousand Nine Hundred Ninety-Nine and No/100
                  Dollars ($1,908,999.00), to be distributed approximately in
                  accordance with the schedule attached as Exhibit II. SPONSOR
                  acknowledges that the distribution of such expenses may be
                  modified.

         4.       CANCER CENTER acknowledges that $760,000 of the fee of One
                  Million Nine Hundred Eight Thousand Nine Hundred Ninety-Nine
                  and No/100 Dollars ($1,908,999.00), for research expenses and
                  other related costs was received on December 15, 1994. SPONSOR
                  and CANCER CENTER agree that the remaining $1,148,999.00,
                  shall be due and payable as follows: (1) $287,249.75 shall be
                  due on April 1, 1995, (2) $287,249.75 shall be due on August
                  1, 1995, and (3) $287,249.75 shall be due on December 1, 1995.

         OTHERWISE, the terms and provisions of the original Agreement executed
on the 11th of February, 1993 and amended on the 20th day of July, 1994 by and
between the parties shall in full force and effect, provided, however, that in
the event of a conflict in the terms and conditions between this Amendment No. 2
and the Sponsored Research Agreement, the terms and conditions of this Amendment
shall prevail.

<PAGE>   12

         IN WITNESS WHEREOF, the parties have executed two (2) original
counterparts of this Amendment No. 2, each of which are of equal dignity and
effective a of the date first hereinabove written.

SPONSOR                                THE UNIVERSITY OF TEXAS SYSTEM
                                       M.D. ANDERSON CANCER CENTER

BY:/s/ DAVID NANCE                     BY:/s/ MICHAEL J. BEST
-----------------------------------       --------------------------------------
       David Nance                              Michael J. Best
       President                                Chief Financial Officer
       Introgen Therapeutics, Inc.

                                      I have read this amendment and understand
                                      my obligations hereunder:

                                       BY:/s/ JACK A. ROTH
                                          --------------------------------------
                                                Jack A. Roth, M.D.
                                                Principal Investigator

                                       BY:/s/ HELMUTH GOEPFERT
                                          --------------------------------------
                                                Helmuth Goepfert, M.D.
                                                Ad Interim Head, Div. of Surgery

                                       CONTENT APPROVED:

                                       BY:/s/ DONNA S. GILBERG
                                          --------------------------------------
                                                Donna S. Gilberg, CPA
                                                Manager, Sponsored Programs

Payment Mailing Address:

The University of Texas
M.D. Anderson Cancer Center
Attention:  Manager, Sponsored Programs
P.O. Box 297402
Houston, Texas 77297

Tax ID:  74-6001118-A1

                                       -2-

<PAGE>   13

                                    EXHIBIT I

                                       [*]

     [*]   Certain information on this page has been omitted and filed
            separately with the Commission. Confidential treatment has been
            requested with respect to the omitted portions.
<PAGE>   14

                                 AMENDMENT NO. 3

                                       TO

                          SPONSORED RESEARCH AGREEMENT

         AMENDMENT, effective this 31st day of December, 1995, between THE
UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (hereinafter referred to as
"CANCER CENTER"), a component of THE UNIVERSITY OF TEXAS SYSTEM (hereinafter
referred to as "SYSTEM") located at Houston, Texas, and INTROGEN THERAPEUTICS
(hereinafter referred to as "SPONSOR"), of the Sponsored Research Agreement made
by these parties and dated the 11th day of February, 1993 and subsequently
amended, regarding research on the evaluation and study of the "Development of
Therapeutic Treatment and Prevention of Lung Cancer".

         1.       CANCER CENTER and SPONSOR agree that the period of work
                  identified in the Original Sponsored Research Agreement shall
                  be extended to December 31, 1996.

         2.       CANCER CENTER and SPONSOR agree that the work to be done
                  during this extended work period will be performed according
                  to the procedures described in the revised workscope, the
                  title of which is "Development of Gene Therapeutic Treatment
                  and Prevention for Cancer", a copy of which is attached hereto
                  as Exhibit I and incorporated herein by reference. The
                  workscope has been amended and approved in accordance with
                  institutional Policy.

         3.       CANCER CENTER and SPONSOR agree that the specific additional
                  costs associated with this work shall be One Million Five
                  Hundred Ninety-Eight Thousand Eight Hundred Twenty-One and
                  No/100 ($1,598,821.00), to be distributed approximately in
                  accordance with the schedule attached as Exhibit II. SPONSOR
                  acknowledges that the distribution of such expenses may be
                  modified.

         4.       CANCER CENTER and SPONSOR agree that the fee of One Million
                  Five Hundred Ninety-Eight Thousand Eight Hundred Twenty-One
                  and No/100 ($1,598,821.00) for research expenses and other
                  related costs shall be due and payable by SPONSOR and CANCER
                  CENTER, but at a minimum in the following amount on the
                  following dates. (1) $399,704.25 shall be due January 1, 1996,
                  (2) $399,704.25 shall be due April 1, 1996, (3) $399,704.25
                  shall be due July 1, 1996 and (4) $399,704.25 shall be due
                  October 1, 1996.

         5.       Access to Information. All results of and information arising
                  from the Research shall be made available and accessible to
                  SPONSOR by CANCER CENTER. SPONSOR shall have the right to
                  obtain copies or duplicates of such results and information on
                  a timely basis, in either written or electronic form, upon
                  SPONSOR giving CANCER CENTER reasonable notice of SPONSOR"s
                  desire to obtain such results and information.

         OTHERWISE, the terms and provisions of the original Agreement executed
on the 11th day of February, 1993 and subsequently amended by and between the
parties hereto shall remain in full force and effect, provided, however, that in
the event of a conflict in the terms and conditions between this Amendment No. 3
and the Sponsored Research Agreement the terms and conditions of this Amendment
shall prevail.

<PAGE>   15

         IN WITNESS WHEREOF, the parties have executed two (2) original
counterparts of this Amendment No. 3, each of which are of equal dignity and
effective as of the date first hereinabove written.

INTROGEN THERAPEUTICS, INC.           THE UNIVERSITY OF TEXAS
                                      M.D. ANDERSON CANCER CENTER

BY:/s/ DAVID NANCE                    BY:/s/ MICHAEL J. BEST
   -------------------------------       ---------------------------------
       David Nance                             Michael J. Best
       President                               Chief Financial Officer
       Introgen Therapeutics, Inc.

                                      I have read this
                                      amendment and
                                      understand my
                                      obligations hereunder:

                                       BY:/s/ JACK A. ROTH
                                          ---------------------------------
                                                Jack A. Roth, M.D.
                                                Principal Investigator

                                       BY:/s/ HELMUTH GOEPFERT
                                          ---------------------------------
                                                Helmuth Goepfert, M.D.
                                                Ad Interim Head, Div. of Surgery

PAYMENT MAILING ADDRESS:
         The University of Texas
         M.D. Anderson Cancer Center
         Atten: Manager, Sponsored Programs
         P.O. Box 297402
         Houston, Texas 77297
         Tax ID: 74-6001118-Al

                                       -2-

<PAGE>   16

                                    EXHIBIT I

                                       [*]

     [*]   Certain information on this page has been omitted and filed
            separately with the Commission. Confidential treatment has been
            requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}]]